about
Inactivation of human plasma kallikrein and factor XIa by protein C inhibitorProtein C inhibitor may modulate human sperm-oocyte interactionsPharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot studyAnalysis of blood coagulation in mice: pre-analytical conditions and evaluation of a home-made assay for thrombin-antithrombin complexesCrystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulationLow-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over studyDifferential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosisPlatelets in patients with premature coronary artery disease exhibit upregulation of miRNA340* and miRNA624*Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage.Introduction to the analysis of next generation sequencing data and its application to venous thromboembolism.Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor.Hyperferritinaemia in dengue virus infected patients is associated with immune activation and coagulation disturbancesBeta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome.Expression patterns of protein C inhibitor in mouse development.Individual with subclinical atherosclerosis have impaired proliferation of blood outgrowth endothelial cells, which can be restored by statin therapyVascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarkerActivated factor V is a cofactor for the activation of factor XI by thrombin in plasma.The interaction between anticoagulant protein S and complement regulatory C4b-binding protein (C4BP).Overexpression of activated protein C hampers bacterial dissemination during pneumococcal pneumonia.The diagnosis of disseminated intravascular coagulation.Effect of transfusion of fresh frozen plasma on parameters of endothelial condition and inflammatory status in non-bleeding critically ill patients: a prospective substudy of a randomized trial.The effects of continuous venovenous hemofiltration on coagulation activation.Blood transfusion during cardiac surgery is associated with inflammation and coagulation in the lung: a case control study.New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R).Hypercoagulability in the metabolic syndrome.Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinkingLowering blood glucose during hip surgery does not influence coagulation activation.Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study.VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes.The role of ADAMTS13 in acute myocardial infarction: cause or consequence?Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in menEvaluation of coagulation activation after rhinovirus infection in patients with asthma and healthy control subjects: an observational study.Recombinant anticoagulant factors for adjunctive treatment of sepsis.Coagulation factor XI as a novel target for antithrombotic treatment.β(2) -Glycoprotein I: evolution, structure and function.Protein C inhibitor.Recent insights into the role of the contact pathway in thrombo-inflammatory disorders.Novel targets for anticoagulants lacking bleeding risk.Structure-function relationships in thrombin-activatable fibrinolysis inhibitor.The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women.
P50
Q24292993-CC4FEC94-2BE7-497A-A9DA-2020FB55B277Q24318526-1F0419B3-3CFE-49E8-8B0F-E96DCC46C302Q24642002-47017A23-9C33-4139-8E66-D5E0FC0295AAQ24815046-ACEE2437-4B34-415A-B38A-9BDD51FA3A3CQ27650862-C16BB04F-5046-4895-8528-B07710162DA5Q28368332-AB3C4748-1628-44F8-AF2F-4633E24DF485Q28539503-B83F2BD7-34D9-42A1-9D22-5A33BB2FC802Q28743899-3AF1257F-36F2-48BF-9756-1427683DDD8DQ30860676-C15A0449-263F-49AA-85F2-8782212FED9EQ31002832-6DC4B1B2-BC9F-480B-9E10-718B1D6FB795Q31060214-7B347D9C-9AEF-4C98-853B-3B9D9EE284ACQ33418083-7C2F48E7-836C-4E95-B34D-F3BF424E8EDEQ33576496-B3C7EE5A-3284-4B3A-B527-6692D5213408Q33781232-3E48870F-2C65-4AFF-8F53-85ECEE6287B0Q33793376-4E76E580-51D9-41B7-BC78-BAF2E6DD2B1AQ33920807-ACB92185-A329-4623-9E0B-5496EEC8F38AQ33927262-B8768950-3707-4B3D-9310-97908A43A713Q34126336-A2F78F09-196D-4349-81F3-3F1E5870D067Q34491379-E00C7249-CE3C-4959-817B-31B69D863ABDQ34914193-FBD49A3B-A0A8-4060-9B5E-0E3A52964797Q35531996-79EAF435-393B-410F-B2AE-2506EFC8F463Q35544719-FCACDDBC-BC1F-4E16-B06C-CA3FC0618732Q35567004-59AF70CE-8006-4AA1-B66B-426A8CB5A11EQ35661476-D4938C7C-9194-45E2-8494-3A32361DBEBCQ36076184-7B2DB4D3-DA02-42B8-B6B2-CDC8B8EA6375Q36169271-AFC74373-1977-4E20-9BDE-61539A255164Q36323852-49372DF6-832E-46E5-A300-A90283E34514Q36384958-02BE2A01-FAA4-4185-9189-8A0FCA8AA1A1Q36868343-99072F51-F18A-407D-AFFC-A1653607B11AQ37118505-F9E606CE-7995-4991-9FC5-F2D088E06478Q37207774-4EB9405D-2D11-491E-8483-8F247D1EEA37Q37580170-4F98A9E3-6727-4194-9E25-B296EF08F3C6Q37772829-BBB9566D-5FF1-4DAF-AF9B-ABC9AF3F8D49Q37781402-009FF66F-BD9B-4DA5-B379-98F66A25C051Q37871051-67CB6CB2-275B-4CEB-9F9A-E3D80B754812Q37909223-58E46821-B0C9-4E63-A84E-4D1978AF8FDEQ38361576-5D373340-E553-45CC-8DD5-3C5668702007Q38668042-1C90249C-DFF6-4081-86EA-D2E90B2584D1Q38703066-4F289822-6F05-459A-AAC8-5014764D73DCQ39347912-F87EE13A-9BC4-40DD-ABA0-F4C4BC133404
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
J C Meijers
@ast
J C Meijers
@en
J C Meijers
@es
J C Meijers
@nl
type
label
J C Meijers
@ast
J C Meijers
@en
J C Meijers
@es
J C Meijers
@nl
prefLabel
J C Meijers
@ast
J C Meijers
@en
J C Meijers
@es
J C Meijers
@nl
P31
P496
0000-0002-4198-6780